Nature Medicine, Published online: 31 July 2025; doi:10.1038/s41591-025-03853-xThe phase 2 TUXEDO-3 trial identifies the HER3-targeting antibody–drug conjugate patritumab deruxtecan as
Nature Medicine, Published online: 31 July 2025; doi:10.1038/s41591-025-03849-7Multimodal data from 347 deeply phenotyped individuals including healthy, prediabetic individuals and individuals
New findings from King's College London challenge conventional dietary wisdom, revealing that consuming eleven distinct plant varieties each day provides
This acquisition enables ESTEVE CDMO (Esteve Química) to expand its contract development and manufacturing services for small-molecule active pharmaceutical ingredients
Total revenues for the second quarter 2025 increased 11% to $67.2 billion Shareholders' net income for the second quarter 2025
SHENZHEN, China, July 31, 2025 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary,
TAMPA, Fla., July 31, 2025 /PRNewswire/ -- Joseph Spine Institute is proud to announce that its founder, Dr. Samuel A.
Esta adquisición permite a ESTEVE ampliar su oferta de servicios de desarrollo y fabricación por contrato de ingredientes farmacéuticos activos
